Current medications for Inflammatory Bowel Disease (IBD) do not work for all patients
and sometimes stop working after one year. Looking for new cures, clinicians believe
the most promising ones are not actually a new set of drugs, but a change of strategy
with existing therapies. Methotrexate, Azathioprine, Ustekinumab are some of the most
common off-label drugs prescribed for.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Statins associated with decreased risk of new onset inflammatory bowel disease.Am J Gastroenterol. 2016; 111: 1416-1423
- Editorial: statins for inflammatory bowel disease: expanding the scope of prevention.Am J Gastroenterol. 2016; 111: 1424-1426
- Pharmacological actions of statins: a critical appraisal in the management of cancer.Pharmacol Rev. 2012; 64: 102-146
- The gut microbiota and inflammatory bowel disease.Semin Immunopathol. 2015; 37: 47-55
- Ezetimibe and simvastatin modulate gut microbiota and expression of genes related to cholesterol metabolism.Life Sci. 2015; 132: 77-84
- Statin use is associated with reduced risk of colorectal cancer in patients with inflammatory bowel diseases.Clin Gastroenterol Hepatol. 2016; 14: 973-979
Article info
Publication history
Published online: November 14, 2016
Accepted:
November 11,
2016
Received in revised form:
November 8,
2016
Received:
November 4,
2016
Identification
Copyright
© 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
